Radiotherapy and Radiosurgery for Tumors of the Central Nervous System

Surgical Oncology Clinics of North America

Volumn 22, Issue 3, 2013, Pages 445-461

  Kirkpatrick, John P ^a   Yin, Fang Fang ^a   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Brain metastases; Brain tumors; Central nervous system; Intensity modulated radiotherapy; Malignant gliomas; Spine tumors; Stereotactic radiosurgery

Indexed keywords

BEVACIZUMAB; TEMOZOLOMIDE;

BRAIN METASTASIS; BRAIN RADIATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHEMORADIOTHERAPY; DEMENTIA; ERYTHEMA; GLIOBLASTOMA; HAIR LOSS; HUMAN; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; PAROTID ENLARGEMENT; PATIENT SAFETY; PRURITUS; RADIATION INJURY; REVIEW; SPINAL CORD DISEASE; SPINAL CORD TUMOR; SPINE METASTASIS; SPINE TUMOR; STEREOTACTIC RADIOSURGERY; TREATMENT OUTCOME;

BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; PROGNOSIS; RADIOSURGERY; RADIOTHERAPY;

EID: 84876834458     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2013.02.008     Document Type: Review

References (83)

1. Black P.M., Loeffler J.S. Cancer of the nervous system 2005, Lippincott Williams & Wilkins, Philadelphia. 2nd edition.
2. Barnett G.H., Linskey M.E., Adler J.R., et al. Stereotactic radiosurgery-an organized neurosurgery-sanctioned definition. J Neurosurg 2007, 106:1-5.
3. Sperduto P.W., Chao S.T., Sneed P.K., et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010, 77:655-661.
4. Mehta M.P., Paleologos N.A., Mikkelsen T., et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96:71-83.
5. Gaspar L.E., Scott C., Murray K., et al. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 2000, 47:1001-1006.
6. Mikkelsen T., Paleologos N.A., Robinson P.D., et al. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96:97-102.
7. Ryken T.C., McDermott M., Robinson P.D., et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96:103-114.
8. Klein M., Heimans J.J., Aaronson N.K., et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002, 360:1361-1368.
9. Douw L., Klein M., Fagel S.S., et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 2009, 8:810-818.
10. Tsao M.N., Lloyd N., Wong R.K., et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 2012, (4). CD003869.
11. Mintz A.H., Kestle J., Rathbone M.P., et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996, 78:1470-1476.
12. Noordijk E.M., Vecht C.J., Haaxma-Reiche H., et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994, 29:711-717.
13. Patchell R.A., Tibbs P.A., Walsh J.W., et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322:494-500.
14. Patchell R.A., Tibbs P.A., Regine W.F., et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998, 280:1485-1489.
15. Kocher M., Soffietti R., Abacioglu U., et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011, 29:134-141.
16. Andrews D.W., Scott C.B., Sperduto P.W., et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363:1665-1672.
17. Sneed P.K., Suh J.H., Goetsch S.J., et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 2002, 53:519-526.
18. Aoyama H., Shirato H., Tago M., et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006, 295:2483-2491.
19. Aoyama H., Tago M., Kato N., et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 2007, 68:1388-1395.
20. Chang E.L., Wefel J.S., Hess K.R., et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009, 10:1037-1044.
21. Soltys S.G., Adler J.R., Lipani J.D., et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys 2008, 70:187-193.
22. Choi C.Y., Chang S.D., Gibbs I.C., et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control. Int J Radiat Oncol Biol Phys 2012, 84(2):336-342.
23. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
24. CBTRUS Statistical Report: Primary brain and central nervous system tumors diagnosed in the United States in 2004-2008 (March 23, 2012 Revision), 2012.
25. Ricard D., Idbaih A., Ducray F., et al. Primary brain tumours in adults. Lancet 2012, 379:1984-1996.
26. Stummer W., van den Bent M.J., Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir (Wien) 2011, 153:1211-1218.
27. Laperriere N., Zuraw L., Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002, 64:259-273.
28. Walker M.D., Alexander E., Hunt W.E., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978, 49:333-343.
29. Walker M.D., Green S.B., Byar D.P., et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980, 303:1323-1329.
30. Bleehen N.M., Stenning S.P. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991, 64:769-774.
31. Walker M.D., Strike T.A., Sheline G.E. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979, 5:1725-1731.
32. Chang C.H., Horton J., Schoenfeld D., et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983, 52:997-1007.
33. Nelson D.F., Curran W.J., Scott C., et al. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma-possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Biol Phys 1993, 25:193-207.
34. Laperriere N.J., Leung P.M., McKenzie S., et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 1998, 41:1005-1011.
35. Selker R.G., Shapiro W.R., Burger P., et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 2002, 51:343-355. [discussion: 355-7].
36. Souhami L., Seiferheld W., Brachman D., et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004, 60:853-860.
37. Minniti G., Lanzetta G., Scaringi C., et al. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 2012, 83:93-99.
38. Hochberg F.H., Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980, 30:907-911.
39. Shapiro W.R., Young D.F. Treatment of malignant glioma. A controlled study of chemotherapy and irradiation. Arch Neurol 1976, 33. 494-50.
40. Wallner K.E., Galicich J.H., Krol G., et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989, 16:1405-1409.
41. Fine H.A., Dear K.B., Loeffler J.S., et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993, 71:2585-2597.
42. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359:1011-1018.
43. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
44. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
45. Ajay D., Sanchez-Perez L., Choi B.D., et al. Immunotherapy with tumor vaccines for the treatment of malignant gliomas. Curr Drug Discov Technol 2012, 9(4):237-255.
46. Lai A., Tran A., Nghiemphu P.L., et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011, 29:142-148.
47. Vredenburgh J.J., Desjardins A., Reardon D.A., et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 2011, 17:4119-4124.
48. Narayana A., Gruber D., Kunnakkat S., et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg 2012, 116:341-345.
49. Cohen M.H., Shen Y.L., Keegan P., et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009, 14:1131-1138.
50. Kreisl T.N., Kim L., Moore K., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27:740-745.
51. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13:1253-1259.
52. Fogh S.E., Andrews D.W., Glass J., et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 2010, 28:3048-3053.
53. Cabrera H.N., Almeida A.N., Silva C.C., et al. Use of intraoperative MRI for resection of gliomas. Arq Neuropsiquiatr 2011, 69:949-953.
54. Cuneo K.C., Vredenburgh J.J., Sampson J.H., et al. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2012, 82:2018-2024.
55. Gutin P.H., Iwamoto F.M., Beal K., et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009, 75:156-163.
56. Bentzen S.M., Constine L.S., Deasy J.O., et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 2010, 76:S3-S9.
57. Marks L.B., Ten Haken R.K., Martel M.K. Guest editor's introduction to QUANTEC: a users guide. Int J Radiat Oncol Biol Phys 2010, 76:S1-S2.
58. Lawrence Y.R., Li X.A., el Naqa I., et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 2010, 76:S20-S27.
59. Mayo C., Yorke E., Merchant T.E. Radiation associated brainstem injury. Int J Radiat Oncol Biol Phys 2010, 76:S36-S41.
60. Mayo C., Martel M.K., Marks L.B., et al. Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys 2010, 76:S28-S35.
61. Bhandare N., Jackson A., Eisbruch A., et al. Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys 2010, 76:S50-S57.
62. Kirkpatrick J.P., van der Kogel A.J., Schultheiss T.E. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys 2010, 76:S42-S49.
63. Ma L., Sahgal A., Cozzi L., et al. Apparatus-dependent dosimetric differences in spine stereotactic body radiotherapy. Technol Cancer Res Treat 2010, 9:563-574.
64. Nelson J.W., Yoo D.S., Sampson J.H., et al. Stereotactic body radiotherapy for lesions of the spine and paraspinal regions. Int J Radiat Oncol Biol Phys 2009, 73:1369-1375.
65. Wu Q.J., Wang Z., Kirkpatrick J.P., et al. Impact of collimator leaf width and treatment technique on stereotactic radiosurgery and radiotherapy plans for intra- and extracranial lesions. Radiat Oncol 2009, 4:3.
66. Wu Q.J., Yoo S., Kirkpatrick J.P., et al. Volumetric arc intensity-modulated therapy for spine body radiotherapy: comparison with static intensity-modulated treatment. Int J Radiat Oncol Biol Phys 2009, 75:1596-1604.
67. Sahgal A., Bilsky M., Chang E.L., et al. Stereotactic body radiotherapy for spinal metastases: current status, with a focus on its application in the postoperative patient. J Neurosurg Spine 2011, 14:151-166.
68. Sahgal A., Larson D.A., Chang E.L. Stereotactic body radiosurgery for spinal metastases: a critical review. Int J Radiat Oncol Biol Phys 2008, 71:652-665.
69. Ahmed K.A., Stauder M.C., Miller R.C., et al. Stereotactic body radiation therapy in spinal metastases. Int J Radiat Oncol Biol Phys 2012, 82:e803-e809.
70. Hall W.A., Stapleford L.J., Hadjipanayis C.G., et al. Stereotactic body radiosurgery for spinal metastatic disease: an evidence-based review. Int J Surg Oncol 2011, 979214:2011.
71. Sciubba D.M., Petteys R.J., Dekutoski M.B., et al. Diagnosis and management of metastatic spine disease. J Neurosurg Spine 2010, 13:94-108.
72. Bach F., Larsen B.H., Rohde K., et al. Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. Acta Neurochir (Wien) 1990, 107:37-43.
73. Helweg-Larsen S., Sorensen P.S. Symptoms and signs in metastatic spinal cord compression: a study of progression from first symptom until diagnosis in 153 patients. Eur J Cancer 1994, 30A:396-398.
74. Loblaw D.A., Mitera G., Ford M., et al. A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord compression. Int J Radiat Oncol Biol Phys 2012, 84:312-317.
75. Rades D., Blach M., Nerreter V., et al. Metastatic spinal cord compression. Influence of time between onset of motoric deficits and start of irradiation on therapeutic effect. Strahlenther Onkol 1999, 175:378-381.
76. Rades D., Heidenreich F., Karstens J.H. Final results of a prospective study of the prognostic value of the time to develop motor deficits before irradiation in metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 2002, 53:975-979.
77. Patchell R.A., Tibbs P.A., Regine W.F., et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005, 366:643-648.
78. Rades D., Huttenlocher S., Dunst J., et al. Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression. J Clin Oncol 2010, 28:3597-3604.
79. Lutz S., Berk L., Chang E., et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011, 79:965-976.
80. Rades D., Lange M., Veninga T., et al. Final results of a prospective study comparing the local control of short-course and long-course radiotherapy for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 2011, 79:524-530.
81. Sahgal A., Ma L., Gibbs I., et al. Spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 77:548-553.
82. Sahgal A., Weinberg V., Ma L., et al. Probabilities of radiation myelopathy specific to stereotactic body radiation therapy to guide safe practice. Int J Radiat Oncol Biol Phys 2013, 85(2):341-347.
83. Schultheiss T.E. The radiation dose-response of the human spinal cord. Int J Radiat Oncol Biol Phys 2008, 71:1455-1459.